ArticlePLoS computational biology2015
Bacterial temporal dynamics enable optimal design of antibiotic treatment.
Article in PLoS computational biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Hydraulic Pressure-Programmed Molecular Transport in Tough Hydrogels.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Dynamic collateral sensitivity profiles highlight opportunities and challenges for optimizing antibiotic treatments.PLoS biology · 2025Article
- Deciphering the influence of NaCl on social behaviour ofRoyal Society open science · 2024Article
- Sub-inhibitory antibiotic treatment selects for enhanced metabolic efficiency.Microbiology spectrum · 2024Article
- Bacterial memory in antibiotic resistance evolution and nanotechnology in evolutionary biology.iScience · 2023Review
- Mapping single-cell responses to population-level dynamics during antibiotic treatment.Molecular systems biology · 2023Article
- Dimensionless parameter predicts bacterial prodrug success.Molecular systems biology · 2022Article
- Article
- Article
- RESTAMP - Rate estimates by sequence-tag analysis of microbial populations.Computational and structural biotechnology journal · 2021Article
- Predictive biology: modelling, understanding and harnessing microbial complexity.Nature reviews. Microbiology · 2020Review
- Resist or perish: Fate of a microbial population subjected to a periodic presence of antimicrobial.PLoS computational biology · 2020Article
- Article
- Antibiotic interactions shape short-term evolution of resistance in E. faecalis.PLoS pathogens · 2020Article
- Integrating mathematical models with experimental data to investigate the within-host dynamics of bacterial infections.Pathogens and disease · 2019Review
- Pervasive and diverse collateral sensitivity profiles inform optimal strategies to limit antibiotic resistance.PLoS biology · 2019Article
- Dynamic linear models guide design and analysis of microbiota studies within artificial human guts.Microbiome · 2018Article
- Robust, linear correlations between growth rates and β-lactam-mediated lysis rates.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- Interplay between Antibiotic Efficacy and Drug-Induced Lysis Underlies Enhanced Biofilm Formation at Subinhibitory Drug Concentrations.Antimicrobial agents and chemotherapy · 2018Article
- Quantitative and synthetic biology approaches to combat bacterial pathogens.Current opinion in biomedical engineering · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
There is a critical need to better use existing antibiotics due to the urgent threat of antibiotic resistant bacteria coupled with the reduced effort in developing new antibiotics. β-lactam antibiotics represent one of the most commonly used classes of antibiotics to treat a broad spectrum of Gram-positive and -negative bacterial pathogens. However, the rise of extended spectrum β-lactamase (ESBL) producing bacteria has limited the use of β-lactams. Due to the concern of complex drug responses, many β-lactams are typically ruled out if ESBL-producing pathogens are detected, even if these pathogens test as susceptible to some β-lactams. Using quantitative modeling, we show that β-lactams could still effectively treat pathogens producing low or moderate levels of ESBLs when administered properly. We further develop a metric to guide the design of a dosing protocol to optimize treatment efficiency for any antibiotic-pathogen combination. Ultimately, optimized dosing protocols could allow reintroduction of a repertoire of first-line antibiotics with improved treatment outcomes and preserve last-resort antibiotics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.